The
The results missed
The drug developer posted revenue of
Xoma shares have declined 22% since the beginning of the year. The stock has climbed 44% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from
Copyright by Automated Insights, Inc. All rights reserved., source